149 related articles for article (PubMed ID: 38246813)
1. Non-invasive testing and risk-stratification in patients with MASLD.
Zoncapè M; Liguori A; Tsochatzis EA
Eur J Intern Med; 2024 Apr; 122():11-19. PubMed ID: 38246813
[TBL] [Abstract][Full Text] [Related]
2. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
3. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
5. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
[TBL] [Abstract][Full Text] [Related]
6. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice.
Lazarus JV; Castera L; Mark HE; Allen AM; Adams LA; Anstee QM; Arrese M; Alqahtani SA; Bugianesi E; Colombo M; Cusi K; Hagström H; Loomba R; Romero-Gómez M; Schattenberg JM; Thiele M; Valenti L; Wong VW; Yilmaz Y; Younossi ZM; Francque SM; Tsochatzis EA
JHEP Rep; 2023 Jan; 5(1):100596. PubMed ID: 36644239
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
Arora A; Sharma P
J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
[TBL] [Abstract][Full Text] [Related]
10. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
Eur Radiol; 2023 Nov; ():. PubMed ID: 37987833
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
12. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
[TBL] [Abstract][Full Text] [Related]
13. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
[TBL] [Abstract][Full Text] [Related]
14. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
Rhodes FA; Trembling P; Panovska-Griffiths J; Tanwar S; Westbrook RH; Rodger A; Rosenberg WM
J Gastroenterol Hepatol; 2021 Jun; 36(6):1435-1449. PubMed ID: 33171534
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
16. AGILE SCORES IN MASLD AND ALD: EXTERNAL VALIDATION AND THEIR UTILITY IN CLINICAL ALGORITHMS.
Papatheodoridi M; De Ledinghen V; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; Delamarre A; Pinzani M; Tsochatzis EA
J Hepatol; 2024 May; ():. PubMed ID: 38789011
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis.
Al Danaf L; Hussein Kamareddine M; Fayad E; Hussain A; Farhat S
World J Hepatol; 2022 Apr; 14(4):744-753. PubMed ID: 35646268
[TBL] [Abstract][Full Text] [Related]
18. Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study.
Solomon A; Negrea MO; Cipăian CR; Boicean A; Mihaila R; Rezi C; Cristinescu BA; Berghea-Neamtu CS; Popa ML; Teodoru M; Stoia O; Neamtu B
Healthcare (Basel); 2023 Oct; 11(19):. PubMed ID: 37830733
[TBL] [Abstract][Full Text] [Related]
19. Limitations of non-invasive tests for assessment of liver fibrosis.
Patel K; Sebastiani G
JHEP Rep; 2020 Apr; 2(2):100067. PubMed ID: 32118201
[TBL] [Abstract][Full Text] [Related]
20. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis.
Crossan C; Majumdar A; Srivastava A; Thorburn D; Rosenberg W; Pinzani M; Longworth L; Tsochatzis EA
Liver Int; 2019 Nov; 39(11):2052-2060. PubMed ID: 31332938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
